---
title: "Market Insight | KEYMED BIO-B Surges Over 6% Signs Exclusive Licensing Agreement with Belenos Overseas Licensing Two Self-Immunotherapy Drugs"
description: "KEYMED BIO-B is now up more than 6%, as of the deadline for submission, up 5.88% to HKD 33.3, with a turnover of HKD 170.38 million. On the news front, on July 9th, KEYMED announced that it has entere"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/209066654.md"
published_at: "2024-07-17T04:01:03.000Z"
---

# Market Insight | KEYMED BIO-B Surges Over 6% Signs Exclusive Licensing Agreement with Belenos Overseas Licensing Two Self-Immunotherapy Drugs

> KEYMED BIO-B is now up more than 6%, as of the deadline for submission, up 5.88% to HKD 33.3, with a turnover of HKD 170.38 million. On the news front, on July 9th, KEYMED announced that it has entered into a licensing agreement with Belenos Biosciences, granting the latter exclusive rights to research, develop, register, produce, and commercialize the dual-antibody products CM512 and CM536 globally (excluding Greater China). It is reported that as consideration, KEYMED will receive a $15 million upfront payment and near-term payments, while its wholly-owned subsidiary One Bridge Hong Kong will receive approximately 30.01% equity in Belenos; in addition, depending on the development, regulatory, and commercial milestones of the project, KEYMED may also receive up to an additional $170 million

According to the information from the Wise Finance APP, KEYMED BIO-B (02162) is now up more than 6%, as of the time of publication, it has risen by 5.88% to HKD 33.3, with a turnover of HKD 170.38 million.

On the news front, on July 9th, KEYMED BIO announced that it has entered into a licensing agreement with Belenos Biosciences, granting the latter exclusive rights to research, develop, register, produce, and commercialize the dual antibodies CM512 and CM536 globally (excluding Greater China).

It is reported that as consideration, KEYMED BIO will receive a down payment and recent payments totaling USD 15 million, and its wholly-owned subsidiary, One Bridge Hong Kong, will receive approximately 30.01% of Belenos' equity. In addition, depending on the development, regulatory, and commercial milestones of the project, KEYMED BIO is also expected to receive up to an additional USD 170 million in payments

### Related Stocks

- [02162.HK - KEYMED BIO-B](https://longbridge.com/en/quote/02162.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 約翰·F·肯尼迪遇刺案的新視頻可能證明有第二名槍手參與 | 一段新曝光的 8 毫米膠捲，關於肯尼迪總統遇刺事件，聲稱被聯邦當局隱藏，可能顯示在草坪山上的第二名射手。這段由奧維爾·尼克斯拍攝的錄像捕捉到一個模糊的身影，自 1978 年以來未曾公開。尼克斯的 granddaughter 正在起訴美國政府 | [Link](https://longbridge.com/en/news/276356301.md) |
| 緬因州疾病控制與預防中心報告稱，緬因州已確認新增 4 例麻疹病例 | 緬因州疾病控制中心：緬因州新增 4 例麻疹確診病例，目前實驗室確認的病例總數達到 5 例 | [Link](https://longbridge.com/en/news/276163950.md) |
| 由於巴西咖啡豐收的預期，咖啡價格大幅下跌 | 咖啡價格因巴西豐收的前景而暴跌 | [Link](https://longbridge.com/en/news/276149567.md) |
| 科學家們展示了通過播放合適的聲音，可以在夢中解決問題 | 西北大學的研究人員證明，在睡眠期間播放特定的聲音提示可以影響夢境內容並增強解決問題的能力。在一項涉及 20 名參與者的研究中，那些夢中包含與音頻相關的難題的參與者，其解題率從 20% 翻倍至 40%。這一技術被稱為目標記憶再激活（TMR）， | [Link](https://longbridge.com/en/news/276155069.md) |
| 研究發現，間歇性禁食可能對減肥無效 | 一項大型綜述表明，間歇性禁食可能對超重或肥胖個體的減重效果並不顯著。研究人員分析了 22 項涉及近 2000 名成年人的研究，發現與常規飲食相比，體重減輕沒有顯著差異。此外，他們還審查了 63 篇關於禁食對大腦功能影響的文章，得出的結論是， | [Link](https://longbridge.com/en/news/276152258.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
